Thomas J. Kipps
Research in finding more effective treatments and cures for blood cancers is proceeding at an extraordinary and positive pace.
In my laboratory at UCSD Center for Novel Therapeutics — which leads the nation in blood cancer research — we are pursuing many innovative approaches. We now better understand the effects of genetics, immunity and diet on the course of cancer.
We have demonstrated the effects of specific genes on cancer, and have developed new genetic therapies that may reverse the lethal nature of this dreaded disease.
To continue our pace of research, we constantly recruiting the most talented scientists in the world to join our team at the Center for Novel Therapeutics.
The key to our success lies in exploring every potential avenue to a cure.
Simply put, the more scientists we can train, attract and support to help us, the sooner we will find the treatments that will control cancer.
First laboratory to develop ROR1 antibody now used in CLL clinical trial at the UCSD Moores Cancer Center
A protein which is used to determine the aggressiveness of CLL (Chronic Lymphocytic Leukemia) and course of the disease
The first laboratory to understand the micro-environment of leukemic cells and the “nurse-like” cells that support them
Leadership of the CLL Research Consortium which includes 9 prestigious universities studying the cause and treatment of CLL
Conducted the first human therapy correcting genetic defects involved in CLL at the UCSD Moores Cancer Center
Key member of the research team that identified familial genetic links to CLL, showing the higher risk of developing the disease within families